Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Recent treatment approvals for metastatic and advanced urothelial carcinoma

Vadim Koshkin, MD, University of California San Francisco, San Francisco, CA, provides an overview of the recent approvals for the treatment of metastatic urothelial carcinoma (mUC). Since 2019 three agents have been approved including Erdafitinib for the treatment of patients with FGFR alterations in early 2019. Enfortumab vedotin gained accelerated approval in late 2019 for all patients following a large Phase III trial. Sacituzumab govitecan was approved in 2021 for patients with advanced or metastatic urothelial carcinoma following progression on platinum-base chemotherapy or immune checkpoint inhibitors. There are currently various other targets under active explorations, such as those targeting HER2. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.